C-MU2KNRG Therapeutics
mitochondrial biology, mPTP inhibition, oral small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MU2K
C-MU2KC-MU2Kmitochondrial biology, mPTP inhibition, oral small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Meet Co Founder and CEO Dr Neil Miller and Co Founder and CSO Dr Richard Rutter in this overview of NRG Therapeutics based at Stevenage Bioscience Catalyst. NRG is developing next generation medicine to treat diseases such as Parkinson's, ALS and MND.
5-minute presentations from the six finalists of the 2023 Genesis BioNewsRound – Neil Miller, NRG Therapeutics – Roberto Zanchi, Quadram Institute – Kat Arney, Etcembly – Amanda Lehmann, Astex – Steve Gardner, Precision Life – John McCafferty, Maxion Therapeutics
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gal … in Resources Blog Journalists RSS NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease News provided by NRG Therapeutics May 30, 2022, 03:00 ET Share this article Share to X Share this article Share to X £2.68 million Biomedical Catalyst (BMC) early-stage award funded in part by Innovate UK to support development of disease-modifying medicines for debilitating chronic neurodegenerative disorders NRG has a p … to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68 million early-stage BMC award part-funded by the government-backed agency Innovate UK will support a 24-month project, commencing this month. NRG is applying groundbr … the Parkinson's Virtual Biotech, the drug development arm of Parkinson's UK and grant funding from The Michael J. Fox Foundation and now, Innovate UK. Dr Arthur Roach , Director of Research at Parkinson's UK and a Board member of NRG Therapeutics, said , "What has limited the pharmaceutical industry to date from exploring mPTP inhibitors as novel therapeutic treatments, has been the poor central nervous system (CNS) penetration of known mPTP inhibitors. NRG's small molecules … in this field to develop first-in-class CNS-penetrant mPTP inhibitors." The BMC award (of which NRG contributes 30% of the funding) will, over 24 months, advance NRG's proprietary mPTP inhibitors from lead optimisation through to completion of IND-enabling GLP-toxicology studies with its lead asset. Specifically, it will generate a preclinical da
NRG doses first participants in Phase I trial for ALS and Parkinson’s Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produc
🚀 Biotech on the Move: CHARM Therapeutics, NRG Therapeutics and BoobyBiome | George Costard LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Link … ’s Funding: Closed $67M Series B led by SV Health Investors' Dementia Discovery Fund (DDF) Pipeline: NRG5051 entering first-in-human trials in early 2026 👶 BoobyBiome (London) Focus: Breast milk microbiome for infant gut and immune health Funding: Raised €2.8M Seed Round led by Empirical Ventures Breakthrough: World’s largest breast milk microbiome database + proprietary strain biobank Sharing recognition for dedication to these businesses; Sarah Skerratt, FRSC Nick Edmunds … neuroscience biotech company led Co-founder & CEO Neil Miller & CFO/Coo Grant Hawthorne . Developing mitochondria-targeted small molecule therapeutics for neurodegenerative diseases. The company’s proprietary technology focuses on inhibiting the mitochondrial permeability transition pore (mPTP) to protect neurons from cell death - a key factor in diseases like Parkinson’s disease, ALS (MND), and other chronic neurological conditions. 💰 Total Funding – NRG Therapeutic … nnounced September 2025). 📈 Investors: SV Health Investors' Dementia Discovery Fund (DDF) , The Michael J. Fox Foundation for Parkinson's Research , TARGET ALS FOUNDATION, INC . Omega Funds , Innovate UK , Parkinson's UK 🚀 The new capital will be used to: 1️⃣ Advance NRG-001 into first-in-human clinical trials for Parkinson’s disease 2️⃣ Deliver proof of concept for ALS/MND assets 3️⃣ Expand the company’s mitochondrial drug discovery pipeline 4️⃣ Support preclinical and reg … financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital , WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomic
“It has the potential to stop or slow Parkinson’s.” NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s. The Parkinson’s UK Virtual Biotech originally invested £1 million in 2019, and is now working in partnership with the Parkinson's Foundation. Dr Lynsey Bilsland is here to tell you more about the drug, how we remain an active founding investor and the next steps. | Parkinson's UK
NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project... - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Jun 30, 2022 NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project... NRG Therapeutics Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, and Domainex Ltd., … owing NRG receiving a £2.68 million early-stage Biomedical Catalyst (BMC) award funded by government-backed agency Innovate UK. Previous work carried out by NRG Therapeutics, which was funded by Parkinson’s Virtual Biotech, the drug development arm of Parkinson’s UK, has led to the identification of a number of small molecule lead series which inhibit mitochondrial permeability transition pore (mPTP). The mPTP is a transmembrane protein located in the mitoch
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders April 19, 2023 | 4 min read Twitter LinkedIn Facebook Email Print NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondria … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and LinkedIn . Twitter LinkedIn Facebook Email Print People Healthcare Europe LATEST Layoff Tracker Sangamo slashes 51 jobs amid bankruptcy filing June … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND September 5, 2024 | 4 min read Twitter LinkedIn Facebook Email Print STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neur … ial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis (ALS) (also known as Lou Gehrig’s disease or Motor Nuerone Disease). NRG Therapeutics is applying breakthrough science in the field of mitochondria … nical trials for ALS.” Details of the Target ALS 2024 In Vivo Target Validation grant recepients can be found HERE . Media enquiries (for NRG Therapeutics) Sue Charles, Charles Consultants - +44 7968 726585 [email protected] About NRG Therapeutics – http://www.nrgtherapeutics.com NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation and Target ALS, and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND September 8, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside … ongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP) The mPTP is a well-established driver of mitochondrial dysfunction, inflammation, and neuronal death in neur … s B financing. The financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia. DDF was joined by a syndicate of leading international life science venture investors: British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. Founding investor Parkinson’s UK via i … k), Charlotte Kremers (M Ventures) and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board of directors. In addition, the company is delighted that Professor David Dexter, Director of Research at Parkinson’s UK, has been appointed as a special advisor on Parkinson’s. Caption: NRG Therapeutics’ founding team: left to right Ri
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders February 9, 2023 | 3 min read Twitter LinkedIn Facebook Email Print NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, today a … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and LinkedIn . Twitter LinkedIn Facebook Email Print LATEST Layoff Tracker Sangamo slashes 51 jobs amid bankruptcy filing June 23, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Parkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Parkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme August 25, 2021 | 5 min read Twitter LinkedIn Facebook Email Print NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, today announced further equity … herapeutics is a private company with equity investment from Parkinson’s UK and grant funding from The Michael J. Fox Foundation. Follow us on Twitter and LinkedIn . About Parkinson’s and Parkinson’s UK Parkinson’s is what happens when the brain cells that make dopamine start to die. There are more than 40 symptoms, from tremor and pain to anxiety. Some are treatable, but the drugs can have serious side effects. It gets worse over time and there’s no cure. Yet. Parkinson’s is … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies October 23, 2025 | 5 min read Twitter LinkedIn Facebook Email Print STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company t … s recent £50m series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) in a syndicate of leading international life science venture investors that also included British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. The new funds provide runway for completion of a Phase 2 clinical proof of concept study of NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neuron di … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes. Follow us on LinkedIn . Twitter LinkedIn Facebook Email Print Europe People Neuroscience LATEST Layoff Tracker Sangamo slashes 51 jo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases October 31, 2024 | 4 min read Twitter LinkedIn Facebook Email Print First development candidate selected, NRG5051, with … brain prevents neuronal cell death and reduces neuroinflammation in animals $5M grant from The Michael J. Fox Foundation (MJFF) to advance NRG5051 into the clinic Grant will support CMC, GLP Toxicology, development of a PET tracer and building a biomarker strategy for Parkinson’s NRG5051 anticipated to enter first-in-human clinical studies by end of 2025 STEVENAGE, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company tar … mination of its first development candidate, NRG5051 and has been awarded a $5M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. NRG5051 also has potential in other neurological diseases such as ALS (also known as MND). NRG5051 is a first-in-class inhibitor of the mitochondrial permeability transition pore (mPTP) and is designed to penetrate the brain … d significantly reduces the neuroinflammation observed in these diseases. NRG’s grant from MJFF’s Therapeutics Pipeline Program will fund the completion of key IND-enabling studies with the aim of advancing NRG5051 into first-in-human clinical studies in 2025. This new grant will support the manufacture of drug substance for both 28-day GLP-toxic
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUB … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s January 8, 2026 | 3 min read Twitter LinkedIn Facebook Email Print STEVENAGE, United Kingdom, Jan. 08, 2026 (GLO … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes. Follow us on LinkedIn . Twitter LinkedIn Facebook Email Print Europe Clinical research Patient recruitment Phase 1 Neuroscience ALS … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NRG Therapeutics Announces International Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NRG Therapeutics Announces International Scientific Advisory Board March 30, 2023 | 5 min read Twitter LinkedIn Facebook Email Print NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory … s and Nitrase Therapeutics and is a venture partner with the Dementia Discovery Fund. He was awarded his Ph.D. in chemistry from Harvard University. Melanie Leitner Ph.D. Melanie has over 20 years cross-functional experience in the academic, government, industry, and non-profit sectors, specializing in the neuroscience sector with particular expertise in ALS. She currently serves as the Chief Scientific Officer for the ALS Investment Fund (a life sciences VC) and is the Found … Founder of Accelerating NeuroVentures, LLC. Prior to joining the ALS Investment Fund, Dr. Leitner was an advisor to Target ALS and served as Chief Scientific Officer for the ALS non-profit Prize4Life. She has also held Director positions at Biogen and at the non-profit organizations FasterCures and the Society for Neuroscience. She is a Board observer on the Boards of Verge Genomics, QurAlis, and Bloom Science. Melanie was awarded a Howard Hughes Predoctoral Fellowship as wel … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and LinkedIn . Twit
Sarah Almond, NRG Therapeutics | Careers in Discovery Cancel Home Subscribe Profile Careers in Discovery https://feed.podbean.com/careers-in-discovery/feed.xml 15.6K Downloads 210 Episodes Share RSS Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influential figures, the work they are doing, how they got to where they are and what advice they’d give their younger selves. Brought to you by Singular: Building Brilliant Biotechs. Connect with us at: LinkedIn: http
NRG Therapeutics | Stevenage Bioscience Catalyst Skip to content Search for: About Board and Team Contact Us Getting Here Careers Stevenage Ecosystem Campus Who’s Here Support Business Support Scientific Support Space Accommodation Lab Hotel Incubator Building Spark Building Accelerator Building Amenities News Latest updates Events Publications Sustainability Accelerate Start up Alumni Members About Board and Team Contact Us Getting Here Careers Stevenage Ecosystem Campus Who’s Here Support Business Support Scientific Support Space Accommodation Lab Hotel Incubator Building Spark B
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
NRG Therapeutics hires three senior staff for NRG5051 clinical trials | US Life Science Jobs - PharmiWeb.Jobs posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin
Instagram Instagram Log In Sign Up Close Never miss a post from nucleate.au Sign up for Instagram to stay in the loop. Sign up Log in nucleate.au • Follow More options nucleate.au 29w We’re excited to share more details about the speaker sessions for our upcoming Customer Discovery Night, hosted in partnership with Cicada Innovations. This event brings together leaders from academia, med-tech, life sciences, and biotech entrepreneurship. 10-Minute Presentations + Q&A: Our first two sessions feature short presentations followed by audience Q&A: - Guy Ford: Professor and MBA Program Dire
Pharmafocus November 2024 Home Articles Magazines Log in Pharmafocus November 2024 ... Published on 15 November 2024 Description: Welcome to Pharmafocus November 2024! 36 articles from this collection: Survey from Roche finds worryingly low understandings about HPV and cervical cancer Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it. PMEA Https://pmeaawards.com/table_booking/ Best-in-cla … ase NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox foundation for Parkinson’s research (MJFF). Bayer and Liveo Research pair to launch new sustainable blister packaging The partnership between the two companies has resulted in the launching of a first-of-its-kind blister packaging, utilising polyethylene terephthalate (PET) instead of the more traditional poly vinyl chloride (PVC). Disrupting drug discovery: to take o … y immune complex membranoproliferative glomerulonephritis (ic-mpgn). Rallybio’s application for a phase 2 trial in pregnant women approved Clinical-stage biotech company Rallybio corporation has announced that it has received approval from two regulatory bodies for its clinical trial applications (CTAS) for a phase 2 study involving pregnant women. CHMP adopts positive opinion for new breast cancer drug, Kisquali, from Novartis Last month, the Committee for Medicinal Products
%PDF-1.7 %���� 168 0 obj > endobj xref 168 91 0000000016 00000 n 0000002733 00000 n 0000002864 00000 n 0000004156 00000 n 0000004247 00000 n 0000004385 00000 n 0000004514 00000 n 0000004653 00000 n 0000004791 00000 n 0000004930 00000 n 0000005069 00000 n 0000005207 00000 n 0000005346 00000 n 0000005485 00000 n 0000005997 00000 n 0000006276 00000 n 0000006541 00000 n 0000006578 00000 n 0000006624 00000 n 0000006738 00000 n 0000006823 00000 n 0000007255 00000 n 0000007819 00000 n 0000009856 00000 n 0000011737 00000 n 0000013186 00000 n 0000014832 00000 n 0000016041 00000 n 0000016714 00000 n 000 … ���*A�~��ߡu��z������ٲux[k�H������D�y endstream endobj 229 0 obj >stream application/pdf One Nucleus Logo_WO_CMYK 2010-04-12T12:06:03+01:00 2010-04-12T12:06:03+01:00 2010-03-26T10:02:18Z Adobe Illustrator CS4 uuid:e2e1cb97-2626-c944-9615-89490cd21133 xmp.did:FC7F1174072068118F62AF8D965E8714 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:2b6b9542-3123-3445-9cbd-aaab4ce791a9 xmp.did:7F9A11D0172068118F62CEC9B2399716 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf co … 8F62CEC9B2399716 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:0 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-07:00 Adobe Illustrator CS4 / saved xmp.iid:FB7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:29:01-07:00 Adobe Illustrator CS4 / saved … C1BF14D1759E83 2008-05-16T15:52:22-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:FA7F117407206811B628E3BF27C8C41B 2008-05-22T13:28:01-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:
Structural Chemistry Data, Software, and Insights | CCDC CCDC Logo Signin Button Search Button Home Software Back Software Explore our structural chemistry software here, to support research in drug discovery, particle behaviour, solid form analysis and functional materials design, all using the world’s largest crystal structure database: the Cambridge Structural Database (CSD). Overview By Field All Software By Field Pharmaceutical Agrochemical Academic Research Crystallography Functional Materials Teaching and Learning By Use Case All Software By Use Case Design Porous Materials Discover New … ional Materials Discover, develop, and characterize molecular materials for any application. Functional Materials Data and Software Teaching and Learning From school children to undergraduates and beyond. Free structural chemistry data and software, with accompanying lesson plans and resources. Data and Software for Teaching and Learning Event Previous Button Event Next Button Professor Jennifer Swift Georgetown University " There's no limit to what you can ask. &qu
Su... - The Michael J. Fox Foundation for Parkinson's Research Facebook Log In The Michael J. Fox Foundation for Parkinson's Research's Post The Michael J. Fox Foundation for Parkinson's Research Verified account November 22, 2019 · Shared with Public Sunovion Pharmaceuticals has just announced the resubmission of a New Drug Application for under-the-tongue apomorphine– a new drug to treat “off” times in Parkinson's. Read more in our latest blog: michaeljfox.org New “Off” Medication Submitted to FDA All reactions: 201 15 comments 61 shares Like Comment Most relevant Ka
NRG Therapeutics targets Parkinson's and ALS with mitochondrial health platform | Longevity.Technology posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking C
Diana Turner, Author at Drug Discovery World (DDW) - Page 21 of 234 Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science Ab
NRG Earns £2.68m Grant Boost For Neurodegenerative Illness --> --> --> --> --> --> --> --> --> --> --> --> Close --> Home Articles Drug Development Manufacturing Supply Chain Facilities Insights Events Contact Us Search Home White Papers Events & Conferences Nutraceutical Contact Us Sign in Welcome! Log into your account your username your password Forgot your password? Get help Password recovery Recover your password your email A password will be e-mailed to you. Pharma Advancement Home Articles Why Standardizing Lab Water Quality is Crucial for Global Pharma R&D Who Are the Major P … mulation Challenges and Innovative Solutions Events Contact Us NRG Earns £2.68m Grant Boost For Neurodegenerative Illness Show Key Takeaways AI Summary NRG Therapeutics, a neuroscience firm, has been presented with the Biomedical Catalyst award. The £2.68 million package will be used to advance the pre-clinical development of the company’s innovative small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND), an … the Terms and conditions and the Privacy policy Please enable the javascript to submit this form WHITE PAPERS Whitepapers Clinerion Patient Network Explorer for Global Healthcare Statistics and HEOR Research The Future of Digital Health Whitepapers RELATED ARTICLES News Top Picks: GMP Training Companies Elevating North American Pharma Standards News Z-Library and the Reduction of Uninformed Medical Decisions Drug Development Manufacturing Packaging & Logistic Facilities & … er Archive Search Sitemap RSS Feed Advertise Advertise with us List your Events Submit Your Content Download Media Pack Contact Us Subscribe I agree with the Terms and conditions and the Privacy policy Please enable the javascript to submit this form Copyright © Value Media Group 2026 . All rights reserved.
Rupert Sandbrink presents mPTP inhibitor research at ALS/MND Symposium | NRG Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … apeutic potential in preclinical models of ALS. The research was supported by a grant from Target ALS and conducted by Biospective Inc. ➡️ Poster details Poster no.: TST-13 Title: Discovery and characterisation of a novel Mitochondrial Permeability Transition Pore (mPTP) inhibitor in preclinical models of ALS Authors: Richard Rutter , Vad Lazari , Gilles Ouvry , Seth Masters , Rupert Sandbrink , Neil Miller Date/time: Poster Session A, Friday Nov 5, 5:30PM – 7:00PM Pacific Ti … ro-tumorigenic liabilities. 📚 Read the full paper: https://lnkd.in/gnwdqiDy 📩 Submit your paper to the Special Issue: https://lnkd.in/eUKyGbVW #JMP #MolecularPathology #HIFPHDInhibitors #HIFAlphaStabilization #ImmuneRegulation #InflammatorySignaling #TherapeuticPotential 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Willingjet Life Science Limited 1,730 followers 6mo Report this post 🔬 Did you know? Some research studies suggest that dande
Instagram Instagram Log In Sign Up Close Never miss a post from parkinsonsuk Sign up for Instagram to stay in the loop. Sign up Log in parkinsonsuk Verified • Follow More options parkinsonsuk Verified 41w “It has the potential to stop or slow Parkinson’s.” NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s. The Parkinson’s UK Virtual Biotech originally invested £1 million in 2019, and is now working in partnership with the Parkinson's Foundation. Dr Lynsey Bilsland is here to tell you more about the drug,
NRG announces £16m Series A for IND for Parkinson’s and ALS | pharmaphorum Skip to main content Tuesday 23 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research &
NRG Therapeutics raises £50m for ALS/MND and Parkinson's research | SV Health Investors' Dementia Discovery Fund (DDF) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Li … 0m for ALS/MND and Parkinson's research SV Health Investors' Dementia Discovery Fund (DDF) 4,873 followers 9mo Report this post We are excited to lead NRG Therapeutics ’ oversubscribed £50m Series B financing alongside new co-investors British Business Bank , Novartis Venture Fund, M Ventures and Criteria Bio Ventures , with continued support from Omega Funds and Brandon Capital . The financing will advance NRG’s lead asset, NRG5051, a first-in-class oral mitochondrial permea … is post Alterity Therapeutics has secured $20m through a strategic placement to fund ATH-434's development, unpacked by Tylah Tully in Stockhead's latest Break it Down. https://buff.ly/213NHzR #ASX Break it Down: Funding boost for Alterity’s MSA drug candidate - Stockhead stockhead.com.au 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in ExSight Ventures 1,313 followers 9mo Report this post 🚀 Revopsis and the RevMod Revolution: ExSight Ventures … million funding round, with participation from Columbus Venture Partners , EIC Fund, @CDTI_innovacion , Invivo Partners , Takeda, and AdBio partners https://lnkd.in/dU9c8uUu Integra Therapeutics closes a €10.7 million funding round, with participation from Columbus, EIC Fund, CDTI, Invivo, Takeda, and AdBio capital-riesgo.es 15 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in IPOX® 1,405 followers 8mo Edited Report this post BREAKING NEWS: IPOX® … Europe Equity Opportunities ETF (FPXE), the takeover adds +70 bps. alpha to the fund and underscores the ongoing wave of post-IPO M&A in biotech and beyond. Source: https://lnkd.in/eenzsWj2 #IPO #MnA #Healthcare #Biotech #Takeover #ETF #FPXE #IPOMnA #GrowthInfusion #GNDX Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion bloomberg.com
Money on the Move: Sapience Scores $41m Backed by BMS, NexPoint - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press R … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Money on the Move: Sapience Scores $41m Backed by BMS, NexPoint June 2, 2022 | 4 min read | Hannah Chudleigh Twitter LinkedIn Facebook Email Print Courtesy of Getty Images Most money moves happened in Europe this week, including a government-backed award for Parkinson’s d … m. Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research, seed funding for an RNA platform and Series C financing for an orphan central nervous disease treatment company. Sapience Therapeutics Sapience Therapeutics closed a Series B round of financing with $41 million, thanks to new investor NexPoint and existing investors Bristol Myers Squibb , Eshelman Ventures and Kingdon Capital. The funding will accelerate Sap … financing from a host of institutional investors including; Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures and Global Health Investment Corporation (GHIC). NRG Therapeutics Based in Cambridge, England, neuroscience company NRG Therapeutics r eceived the Biomedical Catalyst award . NRG is working on brain-penetrant small molecule inhibitors that target mitochondrial dysfunction t … kinson’s disease and other motor neuron diseases. The $2.87 million early-stage award is partly funded by Innovate UK and will help fund the preclinical development of NRG’s novel small molecule disease-modifying medicines. The award money will support NRG’s 24-month preclinical development project, starting this month. The project will focus on
Healthcare Private Placement and M&A Transactions Review Week Ending September 14, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending … ing in a deal led by SV Health Investors on September 8, 2025. Novartis Venture Fund, M Ventures, Caixa Capital Risc, Criteria Bio Ventures, Omega Funds, Brandon Capital and British Business Bank also participated in the round. The company is an operator of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function. SafeHeal: The company raised EUR 45 million of Series C venture funding in a deal led by M&L Group, Solar Eclipse
NRG gearing up for series A to advance brain-penetrant PTP inhibitors | 2021-08-31 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China&
NRG Therapeutics raises £50M for neurodegeneration treatments | Trade Horizons Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … by neurodegenerative disorders.” Led by SV Health Investors’ Dementia Discovery Fund and joined by British Business Bank, M Ventures, Novartis Venture Fund, and others, the funding will propel NRG’s lead candidate NRG5051 into clinical trials for ALS/MND and Parkinson’s disease starting in early 2026. Read more https://lnkd.in/eaGpkKaM #therapeutics 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Polireddy Uppuluri 8mo Repor … ent family protecting our lead product Nebumet did officially receive the first grant in a major market during the summer holidays 🎉 We will now continue to register the patent in other territories, add it to our renewal schedule and mark relevant products accordingly. Jørund Sollid, CEO Immuvera Therapeutics: "Securing this grant strengthens naturally our IP portfolio, and shows to our partners and investors that our science is novel and are being protected, supporting our
NRG Therapeutics secures funding for development of treatment for neurodegenerative disease Home Articles Magazines Log in News NRG Therapeutics secures funding for development of treatment for neurodegenerative disease NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The inhibitor is a first-in-class mitochondrial permeability transition pore (mPTP), affecting the brain when taken orally. In vitro models have demonstrated that the inhibitor is able to protect mitochondrial function and prevent … demonstrated it significantly reduces neuroinflammation in these diseases. The grant will support manufacturing for the drug substance, with an overall goal of enabling studies that advance NGR5051 into first-in-human clinical studies in 2025. Co-founder and CEO of NRG Therapeutics Dr Neil Miller said, “The selection of our first development candidate is a major milestone for the company. NRG5051 has been shown in vivo in preclinical models of Parkinson’s and ALS to prevent … on of disease in individuals with Parkinson’s and ALS. We are grateful for MJFF grant support to help advance NRG5051 into the clinic as quickly as possible.” The grant will further support the validation and identification of new biomarkers that will be used to determine if NRG5051 is inhibiting the mPTP in the brain in addition to producing the desired effects in clinical trials. A final benefit of the grant is to enable the development of a safe low-dose PET tracer that co
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … testing. The funding round, led by SV Health Investors' Dementia Discovery Fund Search company , will enable the company to take lead compound NRG5051 Search drug through initial proof-of-concept testing in amyotrophic lateral sclerosis Search disease ( ALS Search disease ) and Parkinson's disease Search disease . The financing comes during a challenging period for the biotechnology industry and includes participation from the venture arms of major pharmaceutical co … 2025. The clinical program is receiving additional support through a $5 million grant from the Michael J. Fox Foundation Search company , which will fund initial manufacturing and toxicology work. The foundation grant will also support the development of a labeled form of the drug candidate for positron-emission tomography (PET) imaging, allowing researchers to track where the therapy is active in the central nervous system. The company plans to use some of the clinical trial … ded in 2018 by seasoned drug hunter Neil Miller alongside biotech entrepreneurs Grant Hawthorne and Richard Rutter. The Stevenage-based company initially received seed funding from Parkinson's UK, a nonprofit organization, and has successfully secured additional grant funding from organizations including the Michael J. Fox Foundation Search company . Beyond NRG5051 Search drug , the company is developing a broader pipeline of mPTP Search term -targeting compounds. Miller
NRG Therapeutics Ltd bags £50m in Series B financing - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ X/Twitter This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. LinkedIn This field is for validation purposes and should be left … The oversubscribed financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia. DDF was joined by a syndicate of leading international life science venture investors: British Business Bank , M Ventures , Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital . Founding investor Parkinson’s UK vi … k), Charlotte Kremers (M Ventures) and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board of directors. In addition, the company is delighted that Professor David Dexter, Director of Research at Parkinson’s UK, has been appointed as a special advisor on Parkinson’s. © european biotechnology Thomas Gabrielczyk 8 September 2025 financing ALS Parkinson's SHARE Share on Facebook Share on X Share on WhatsApp Share on LinkedIn Share by Mail YOU MIGHT ALSO LIKE Fin
A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences … ated in NRG’s Series B round, including SV Health Investors’ Dementia Discovery Fund, which led the financing, as well as Omega Funds and the venture arms of Merck KGaA and Novartis. Miller and co-founders Richard Rutter and Grant Hawthorne — the first initials of whom comprise NRG’s name — formed the startup in 2018 after shuttering their previous biotech company, Auspherix. Though a “tough sell” to investors when starting up, NRG was able to survive through grants and inves
--> Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegene
#biotech #pharma #mptp #parkinson #als #mnd #bio2025 #drugdevelopment #biotech #networking #neurodegenerativediseases | NRG Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Co … l Convention June 16-19, 2025. Our CEO Neil Miller , CSO Richard Rutter and COO Grant. Hawthorne look forward to meeting with #biotech industry colleagues, investors and #Pharma partners to provide an update on our progress and future plans for a first-in-human clinical trial of NRG5051. Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore ( #mPTP ) being
#mptp #jpm2025 #biotechshowcase #neurodegenerativediseases #partnering | NRG Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI … se week! Schedule a meeting with CEO Neil Miller , CSO Richard Rutter , and COO Grant. Hawthorne to discuss our pioneering approach to neurodegenerative diseases targeting the mitochondrial permeability transition pore ( #mPTP ). Email - [email protected] #JPM2025 #BiotechShowcase #NeurodegenerativeDiseases #Partnering NRG Therapeutics 4,249 followers 1y Edited Our founding senior team of CEO Neil Miller , CSO Richard Rutter , and COO Grant. Hawthorne will be in San Fr
FDA approves Stealth's mitochondria therapy, a breakthrough for neurodegenerative diseases | NRG Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cli … ce” diagnostics rooted in tissue-level biology. Lanserhof Group secured €95M to fund a global expansion of its longevity-focused health resorts and launch new product lines. Mission Therapeutics raised $13.3M to advance USP30/mitophagy modulator MTX325 toward a Phase 1b study in Parkinson’s disease. Generation Lab raised $11M to scale its “SystemAge”/biological-age diagnostics used by longevity clinics. Blueprint closed a $60M round to package and scale its measurement-heavy … port this post We’re excited to announce that Pangea Bio has been awarded a $1M grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance one of our next-generation TrkB activators for Parkinson’s disease (PD). PD constitutes a large unmet medical need posing a huge disease burden to patients. Current approved pharmacotherapies are largely focused on symptomatic relief with no impact on the progressive loss of dopaminergic neurons. Funding from MJFF’ … tech #LifeSciences #MichaelJFoxFoundation #PangeaBio News - Pangea Bio Receives Grant from the Michael J. Fox Foundation | Pangea Bio pangeabio.com 134 14 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 4,249 followers View Profile Connect Explore related topics Mitochondrial Dysfunction in Neurodegenerative Diseases Therapeutic Targets for Neurodegeneration Recent Breakthroughs in Neurodegenerative Disease Research Neurodegenerative Dis
NRG5051 Completes First-in-Human Trials for ALS/Parkinson's Treatment | NRG Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi
NRG Therapeutics - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln "> NRG Therapeutics Disease-modifying neuro therapeutics targeting mitochondrial dysfunction NRG Therapeutics is developing first-in-class, oral, small molecule neuroprotective therapeutics targeting mitochondrial dysfunction and neuroinflammation for treatment of neurodegenerative and peripheral diseases. Its lead program reduces mitochondrial permeability transition pore (mPTP) formation to restore mitochondrial function. The program has broad potential with initial … iotech investors, including M Ventures, SV Health Investors’ Dementia Discovery Fund, British Business Bank, Novartis Venture Fund, Criteria BioVentures, Omega Funds, Brandon Capital and Parkinson’s UK. Visit NRG Therapeutics Charlotte Kremers Principal Legal Information Site Notice / Imprint Terms of Use Privacy Statement © M Ventures, Amsterdam, The Netherlands Social Networks
Member profile: NRG Therapeutics Ltd | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search secto … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association Member profile: NRG Therapeutics Ltd NRG Therapeutics Ltd Drug Discovery Funding stage: Series A Stevenage Website http … mination of its first development candidate, NRG5051 and has been awarded a $5M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Member news 5 September 2024 NRG Therapeutics awarded grant funding from target ALS to support the development of mPTP inhibitors as novel treatments for ALS/MND Member news 8 January 2026 NRG Therapeutics begins human dosing in trial for ALS/MND and Parkinson's treatment NRG Therapeutics Ltd has announced that the first par
NRG Therapeutics - Brandon Capital Toggle navigation About Team Investment Portfolio Responsible Investing News Perspectives Brandon BioCatalyst Contact Us NRG Therapeutics NRG Therapeutics’ pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP). Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation and extend survival in pre-clinical disease models. Based at the Stevenage Bioscience Catalyst (SBC), UK, NRG Therapeutics is a private company with equity investment from Parkinson’s UK, Omega F … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation and Innovate UK (Biomedical Catalyst Early-Stage Award). Therapeutic Area: Neuroscience www.nrgtherapeutics.com LinkedIn Leadership NRG Therapeutics CEO Neil Miller LinkedIn Brandon Capital Lead Investor Jonathan Tobin LinkedIn Contact Us Melbourne Level 9, 31 Queen Street Melbourne VIC 3000 Phone +61 3 9657 0700 Email: [email protected] Sy
Home - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics energizing drug discovery in neurodegenerative diseases Using our unique insights in neuroscience and mitochondrial biology to develop transformative treatments for patients with neurodegenerative disorders SCIENCE PIPELINE NEWS About us NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative disorders. An innovative, clinical stage neu
Overview - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Science NRG Therapeutics is leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders. We are developing novel ‘next generation’ mitochondrial permeability transition pore (mPTP) inhibitors that are orally bioavailable and brain-penetrant. These inhibitors prevent the mitochondrial gain-of-function toxicity of misfolded TDP-43 and &a
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Oct 23, 2025 NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies Stevenage, UK, 23 October 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to ann … und;50m series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) in a syndicate of leading international life science venture investors that also included British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. The new funds provide runway for completion of a Phase 2 clinical proof of concept study of NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neuron di … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes. Follow us on LinkedIn. Media enquiries Sue Charles, Charles Consultants, +44 7968 726585 EMAIL BACK Terms
Pipeline - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Pipeline With a focus on halting or slowing neurodegenerative diseases, NRG Therapeutics is advancing a pipeline of first-in-class orally bioavailable and CNS-penetrant next-generation mitochondrial permeability transition pore (mPTP) inhibitors with a novel mechanism of action. Our proprietary inhibitors are potent and selective against an undisclosed protein ("protein A"), an essential modulator of the mPTP, and have been show
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Sep 8, 2025 NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongsi … ongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP) The mPTP is a well-established driver of mitochondrial dysfunction, inflammation, and neuronal death i … nancing. The financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia. DDF was joined by a syndicate of leading international life science venture investors: British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. Founding investor Parkinson’s UK … k), Charlotte Kremers (M Ventures) and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board of directors. In addition, the company is delighted that Professor David Dexter, Director of Research at Parkinson’s UK, has been appointed as a special advisor on Parkinson’s. -ends- About NRG Therapeutics NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D progra
Neil Miller - Sejelas Home About Us Clients Candidates Careers Send Your CV Team Blog Contact Us Home About Us Clients Candidates Careers Send Your CV Team Blog Contact Us Get started Neil Miller Neil is a co-founder and CEO of NRG Therapeutics in Cambridge, UK, where he has led the company since 2018. With over 25 years in pharma and biotech, he previously served as Chief Scientific Officer and subsequently CEO of Auspherix Ltd in Stevenage, UK. Earlier in his career he spent 18 years at GlaxoSmithKline (GSK) in senior scientific and leadership roles across the UK and Singapore, including ser … ter CEO. Then, seven years ago, together with my co-founders Richard Rutter and Grant Hawthorne, I founded NRG Therapeutics. NRG is a neuroscience company focused on mitochondrial biology. We are particularly interested in understanding why mitochondria become dysfunctional in neurodegenerative diseases and how that leads to neuronal cell death. Our work centres on the mitochondrial permeability transition pore, or mPTP, which is a key contributor to neuronal degeneration in … ry and establish an early IP position. From there, we were fortunate to receive grant funding from the Michael J. Fox Foundation, which enabled us to do the biology needed to elucidate the mechanism of action (MOA) of our compounds. Further funding from Parkinson’s UK, and the UK Government support via an Innovate UK award helped us move into early lead optimisation. It was very much a step-by-step journey, using each milestone to unlock the next. Congratulations on your rece … 5, we closed a £50 million Series B round led by SV Health’s Dementia Discovery Fund, with participation from the Novartis Venture Fund, M Ventures, British Business Bank, Criteria BioVentures alongside our existing investors. The purpose of that financing is to take our lead molecule, NRG5051, into first-in-human studies and through to Phase 2 proof-of-concept in ALS. We recently announced that we’ve initiated first-in-human dosing, which officially makes us a clinical-stage … t, I knew I wanted to found my own company. I also knew that together, Richard, Grant, and I had complementary skills that made it possible. I’ve never regretted that decision—these past seven years have been the most rewarding of my career. What have been the biggest scientific challenges at NRG, and how did you overcome them? There were two maj
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Feb 22, 2023 NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it … dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG Therapeutics is applying breakthrough science in the field of mitochondrial biology to develop first-in-class treatments for Parkinson’s. Its approach is based on inhibiting the mitochondrial per … inson’s and other neurodegenerative diseases. Having met the goals of the grant it received from MJFF in 2021 , this second grant will support experiments to validate a novel mitochondrial drug target for Parkinson’s. The work will determine whether genetic deletion of this mitochondrial protein in vitro and in vivo protects brain cells, and therefore, whether drug modulation of this protein has the potential to improve Parkinson’s symptoms. The overall goal … with our research funded by MJFF and we are delighted to have received a second award to fund further research to validate the molecular target for our mPTP inhibitors. There is a significant unmet medical need as all current treatments for Parkinson’s control symptoms but do not halt or slow progression of disease. Truly disease-modifying treatments for Parkinson’s and other neurodegenerative diseases remain the holy grail. It is our hope that our work could lead
NRG Therapeutics appoints Dr Jonathan Savidge to board of directors Skip to content Search for: News by category AI Biotech Diagnostics Life sciences Medtech Digital health Robotics Wearables Mental health VR Research Insight Features Opinion Appointments AI Biotech Diagnostics Life sciences Medtech Digital health Robotics Wearables Mental health VR Research Insight Features Opinion Appointments AI Biotech Diagnostics Life sciences Medtech Digital health Robotics Wearables Mental health VR Research Insight Features Opinion Appointments Product news AI Biotech Diagnostics Life sciences Medtech … es like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information. __hssrc session This cookie is set by Hubspot. According to their documentation, whenever HubSpot changes the session cookie, this cookie is also set to determine if the visitor has restarted their browser. If this cookie does not e
NRG Therapeutics CEO Neil Miller on ALS and Parkinson's Breakthroughs | Sejelas posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … NRG from hypothesis to £50M Series B ( SV Health Investors' Dementia Discovery Fund (DDF) -led) via Parkinson's UK & The Michael J. Fox Foundation for Parkinson's Research 🔹 Biomarker wins (NfL data) that unlocked funding in tough biotech markets 🔹 Tackling mPTP science gaps in ALS/Parkinson’s as chemist-turned-CEO 🔹 Personal drive after losing his father to Parkinson’s 🔹 Balancing lean ops, science, and leadership grit It’s a masterclass in neuro biotech resilience … d dementia ( Case Western Reserve University ) ❌ FDA declines to review Moderna application for new flu vaccine ( Melody Schreiber ) 👭 Royal Society calls for public’s help to build Women in STEM history map of the UK ( The Royal Society ) Tune into… 🎧 Why AI, obesity and breast cancer will dominate 2026, with Drug Discovery World 🎧 Biotech Beat NVIDIA in 2025. Can It Do It Again? With Karl Thiel , Tom King, and Tim Beyers 🎧 Mini human brains, termination shock, and ancie … wan Hooper , Penny Sarchet , and guests Carissa Wong , Alec Luhn and Sam Wong . Apply to… 📎 Scientist I/II, Bioconjugation, Abzena 📎 Project Manager I Drug Development, Quotient Sciences 📎 Fermentation Scientist I, Bactobio RSVP… 📆 18.02 | Startup Lab: AI Compliance | London, UK 📆 20.02 | Biocom Global Partnering and Investor Conference | California, USA 📆 27.02 | Innovation in Women’s Health and Femtech | London, UK 🦤 Stay up to date with the latest biotech news. Issu … der & Head of Research. The path from the lab to the patient starts here. ⏳ Deadline: February 27th ▶️ Apply here: https://x-bio.at/ 36 2 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Yissum | The Hebrew University Tech Transfer Company 9,171 followers 4mo Edited Report this post 🎬 New from Yissum | D
NRG Therapeutics Announces International Scientific Advisory Board Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics Cycling NBA Motorsport MMA … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,428.85 -9.00 -0.09% GBP/USD 1.3198 -0.0057 -0.43% GBP/EUR 1.1592 0.0000 0.00% FTSE 250 22,926.47 -270.54 -1.17% AIM 782.59 -11.68 -1.47% GOLD FUTURES 4,139.80 -62.90 -1.50% ADVERTISE … s and Nitrase Therapeutics and is a venture partner with the Dementia Discovery Fund. He was awarded his Ph.D. in chemistry from Harvard University. Melanie Leitner Ph.D. Melanie has over 20 years cross-functional experience in the academic, government, industry, and non-profit sectors, specializing in the neuroscience sector with particular expertise in ALS. She currently serves as the Chief Scientific Officer for the ALS Investment Fund (a life sciences VC) and is the Found … Founder of Accelerating NeuroVentures, LLC. Prior to joining the ALS Investment Fund, Dr. Leitner was an advisor to Target ALS and served as Chief Scientific Officer for the ALS non-profit Prize4Life. She has also held Director positions at Biogen and at the non-profit organizations FasterCures and the Society for Neuroscience. She is a Board observer on the Boards of Verge Genomics, QurAlis, and Bloom Science. Melanie was awarded a Howard Hughes Predoctoral Fellowship as wel … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and LinkedIn . Term
Team - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Team All Management Board SAB Advisors Neil Miller Ph.D. CEO VIEW MORE × Neil Miller Ph.D. CEO Over 25 years’ pharma & biotech experience Industry experience as Senior Director and Head of Chemistry, DMPK and External Discovery at GSK Singapore Prior biotech experience as CEO at Auspherix Ltd (2015-18) Jonathan Savidge Ph.D. Independent Non Executive Chair VIEW MORE × Jonathan Savidge Ph.D. Independent Non Exec … arch Biologist at MSD Prior biotech experience as CSO at Ausperix Ltd (2016-18) Grant Hawthorne COO VIEW MORE × Grant Hawthorne COO Over 20 years’ finance and operations experience CFO at Myricx Pharma, Camphos Therapeutics; Inotec AMD Prior biotech experience as COO at Auspherix Ltd (2014-18) Rupert Sandbrink M.D. Ph.D. CMO VIEW MORE × Rupert Sandbrink M.D. Ph.D. CMO Over 25 years’ pharma & biotech experience Previously, Head of Global Clinical De … utive Director Investment team at SV Health Investors’ Dementia Discovery Fund Over 10 years’ experience across academia, life science consulting, and venture capital, with research expertise in neuroscience Charlotte Kremers, Ph.D. Investor Non Executive Director VIEW MORE × Charlotte Kremers, Ph.D. Investor Non Executive Director Investor at M Ventures Neuroscience expertise serving on multiple M Ventures portfolio boards Florian Muellershausen, Ph.D. Inve … sen, Ph.D. Investor Non Executive Director Managing Partner at Novartis Venture Fund, since 2017 Over 20 years’ experience in Pharma R&D, and venture capital Claudio Nessi Ph.D. Investor Non Executive Director VIEW MORE × Claudio Nessi Ph.D. Investor Non Executive Director Managing Director at Omega Funds Over 25 years’ experience in venture investing in life sciences Laurence Barker, Ph.D. Investor Observer VIEW MORE × Laurence Barker, Ph.D. Inves … estor Observer Partner at SV Health Investors co-leading the Dementia Discovery Fund Over 20 years’ experience across venture, biotech and pharma Gilles Ouvry Ph.D. VP Chemistry VIEW MORE × Gilles Ouvry Ph.D. VP Chemistry 20 years of international medicinal chemistry experience Industry as VP, Discovery Chemistry Evotec and at Galderm
NRG Therapeutics Announces International Scientific Advisory Board - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Mar 30, 2023 NRG Therapeutics Announces International Scientific Advisory Board Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule … s and Nitrase Therapeutics and is a venture partner with the Dementia Discovery Fund. He was awarded his Ph.D. in chemistry from Harvard University. Melanie Leitner Ph.D. Melanie has over 20 years cross-functional experience in the academic, government, industry, and non-profit sectors, specializing in the neuroscience sector with particular expertise in ALS. She currently serves as the Chief Scientific Officer for the ALS Investment Fund (a life sciences VC) and is th … r of Accelerating NeuroVentures, LLC. Prior to joining the ALS Investment Fund, Dr. Leitner was an advisor to Target ALS and served as Chief Scientific Officer for the ALS non-profit Prize4Life. She has also held Director positions at Biogen and at the non-profit organizations FasterCures and the Society for Neuroscience. She is a Board observer on the Boards of Verge Genomics, QurAlis, and Bloom Science. Melanie was awarded a Howard Hughes Predoctoral Fellowship as wel
DRS/A 1 filename1.htm DRS/A Table of Contents As submitted confidentially to the U.S. Securities and Exchange Commission on January 17, 2025, as Amendment No. 3 to the initial confidential submission. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information contained herein remains strictly confidential. Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES … r the symbol “KMTS.” Upon the closing of this offering, an investment fund advised by affiliates of Bain Capital, L.P. will own approximately  % of our common shares (or  % of our outstanding common shares if the underwriters exercise in full their over-allotment option). As a result, we will be a “controlled company” within the meaning of the applicable listing rules of    . See “Management—Controlled Company … and services of our Cardiac Recovery System platform include the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services. The ASSURE patient application engages patients with real-time mobile updates to promote compliance, while the Kestra CareStation remote patient data platform equips healthcare providers with actionable insights to support timely and informed care decisions. Heart Alert Services and ASSU … udes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services, as well as the recently launched ASSURE wearable ECG. Cleared by the FDA on May 7, 2024, the ASSURE wearable ECG provides extended monitoring and valuable insights into a patient’s heart function after they are no longer indicated for a WCD. This non-therapeutic platform suppor … um Intermediate Holdings Corp. and West Affum Holdings Corp. will establish tax residency in Ireland, which will occur following the consummation of this offering. We refer to the above transactions, as well as the transactions incidental to or in connection therewith, collectively as the “Organizational Transactions.” See the sections
BioPharma Updates 15th September, 2025 | SciLeads Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Program Pricing Events Resources 3 2 Blog Case Studies eBooks Webinars Newsletter Company 3 2 About Us Careers Testimonials Partners Press & News Contact Login Free Trial a M Features 3 2 Researcher Profiles Organization Profiles Tradeshow Calendar Search Builder Purchasing Data CRM Integration Solutions 3 2 Sales Marketing Data Analytics CROs API AI Partner Pro … international presence. NanoNewron (NJ, USA) received a $2.5M NIH STTR Phase 2 grant to advance its NN-840 program for Alzheimer’s disease, supporting IND-enabling studies ahead of a planned filing next year. Inkocell Therapeutics (Lausanne, Switzerland) received a $168K grant from Venture Kick to advance its next-generation NK-tailored CAR cell therapy platform aimed at developing scalable, safer, and off-the-shelf treatments for cancer and other serious diseases.&nbs … . Valo Health (MA, USA) received an undisclosed Michael J. Fox Foundation grant to investigate NOD2 as a Parkinson’s target using human datasets and AI to determine optimal target modulation. Dewpoint Therapeutics (MA, USA) raised an undisclosed amount in Series D funding to advance its condensate modulator DPTX3186 into clinical trials for gastric cancer and accelerate development of additional c-mod programs. Emerging Ridge Biotechnologies (CA, USA) emerge … ounced pricing of a private placement of ~$100M to advance its SYNGAP1 program, fund R&D, and support working capital and general corporate purposes. Lucid Diagnostics (NY, USA) announced closing of a $28.75M underwritten public offering to support working capital and general corporate purposes. SELLAS Life Sciences (NY, USA) announced the immediate exercise of warrants for $23.6M in gross proceeds, with new warrants issued in a concurrent private placement. Sirnaomics (M … utics (Melbourne, Australia) announced pricing of a $13.2M private placement to fund non-clinical studies, CMC activities, and clinical and regulatory development of ATH434 for Multiple System Atrophy, as well as for general working capital. Xanadu Bio (PA, USA) raised $11M through a private stock sale to advance its PACE nanoparticle delivery pl
Preclinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferen … iotech collaborations. At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements. This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, op … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ical Biomedical Advanced Research and Development Authority Biomedical Catalyst Fund (UK) Biomica Biomunex Pharmaceuticals Bionaut Labs Biond Biologics BiondVax Bionomics BioNova Pharmaceuticals BioNTech BioNxt Solutions Bioprojet Biose Industrie Biosion Biosplice Biotheus Biotools BioVaxys Bioventure MDC BioVersys BioVie BIRAD Research and Development Company Bird Foundation Blacksmith Medicines Blackstone Medical Blau Pharma Bloom Science Bluebird Bio BlueJay Therapeutics B … apeutics Crohn's and Colitis Foundation of America Crown Bioscience CRT Pioneer Fund CryoPort CSIRO CSL CSL Behring CSPC Megalith Biopharmaceutical CSPC Pharmaceutical Group CStone Pharmaceuticals CTMC Cue Biopharma Cullinan MICA Cullinan Oncology Curacle Curative Biotechnology Cure Network Dolby Acceleration Partners CureVac Curia Curigin Curis
Avenzo Therapeutics raises $60M, T.Rx Capital launches with $77.5M fund | Partnology posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … a new life sciences VC firm chaired by Bob Langer, closed its inaugural $77.5M fund. With early investments in seven U.S. startups, the firm will target oncology, neurology, immunology, and radiopharma at the seed and Series A stage. Dualitas Therapeutics secured a $65M Series A to advance bispecific antibodies for immune and inflammatory diseases. Backers include Versant Ventures and Qiming Venture Partners USA , while Eli Lilly and Company , Chugai Venture Fund (CVF) and A … tics, Inc. filed for an IPO after raising $372M in a Series D. The company will fund Phase 2 trials for schizophrenia and Alzheimer’s psychosis, with data expected in 2026–27. 💬 With big Series A/B raises, new licensing bets, and pivotal trial wins, is the West Coast biotech scene entering a rebound phase — or are we still in cautious mode? We’d love to hear your thoughts in the comments. #BiotechNews #DrugDevelopment #LifeSciences …more 10 1 Comment Like Comment Share Copy … . Meanwhile, Bob Langer's new VC firm, TRX Capital closes $77 million inaugural fund. They've already backed seven U.S. companies and planned to write 5 to $10 million checks at seed and Series 8 stages, focusing on oncology, neurology, immunology and radio, pharma and do all lead. US Therapeutic secured $65 million to develop by specific antibodies for immune and inflammatory diseases, aiming to move one of its lead programs into the clinic within two years. Not all headline … no-gene therapy for brain cancer, alongside $28M in seed funding and a $4M CIRM grant. Recent Layoffs: Kezar Life Sciences plans layoffs and is exploring strategic alternatives after FDA canceled a key meeting on zetomipzomib in AIH; agency requested a hepatic-impairment PK study that could delay the program ~2 years. Deals & Partnerships: Ra
Auspherix Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Auspherix Ltd. Private Company | 2013 | United Kingdom | 10-50 | synchronicityhempoil.com Private Company | 2013 | United Kingdom | 10-50 | synchronicityhempoil.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Auspherix Ltd. Login to view more data 0 Patents (Medical) associated with Auspherix Ltd. Login to view more … on Capital. NRG has also received funding from the Michael J. Fox Foundation, a grant Miller called “validating” of the company’s science. Miller and CSO Richard Rutter worked at GSK together for nearly a decade before moving on to Auspherix, an early-stage anti-infectives company, where they met NRG's now COO. Although mitochondrial dysfunction has been recognized as a hallmark of Parkinson’s for several decades, its exact role has historically been undetermined. Recent rese … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Korro Bio and Frequency Therapeutics to merge Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector Approa … of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply to trade on Nasdaq under the ticker symbol KRRO. Korro Bio has secured commitments from a syndicate of life sciences investors for a planned concurrent $117 million financing, co-led by Surveyor Capital (a Citadel company) and Cormorant Asset Management and participation from Atlas Venture, NEA, Platanus, Qiming Venture Partners USA, MP Healthcare Venture Management, Eventide Asset Managemen … ement, Fidelity Management & Research Company LLC, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and additional investors. The financing is expected to close immediately prior to the completion of the merger. The combined company is expected to have approximately $170 million in cash, cash equivalents and marketable securities at close after estimated transaction expenses. The pro-forma cash balance is expected to pro … o Bio is advancing its lead program for AATD to a clinical trial and intends to submit a regulatory filing in the second half of 2024. AATD is an inherited disease that results from a single genetic defect that manifests itself as a broad spectrum of clinical pathologies. A majority of the patients are diagnosed later in life, having multiple clinical effects including liver disease and lung disease, eventually leading to organ transplant in some cases. Suggested Articl … l, chief financial officer of Korro Bio. “In addition, we will be able to fund our company through several value-creating milestones into 2026.” Proposed merger Pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company and pre-merger Korro Bio stockholders (including those purchasing Korro B
💊Rapport Therapeutics, a leader in a clinical-stage biotechnology, launched less than 18 months ago and now, they’re #NasdaqListed! ⚡$RAPP’s pace reflects an urgency to find new solutions for patients struggling with neurological disorders. 🦖Recently, their team (the Rapptors!) stopped by Nasdaq to celebrate their IPO. Congrats on the milestone! | Nasdaq
📰 UK biotech NRG Therapeutics secured £50M ($67M) to bring its lead drug candidate for Parkinson’s and ALS, NRG-5051, into clinical trials by early 2026. 🤔 Why it matters: If successful, NRG’s… | Joachim Eeckhout LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at … ience. ⏳ Backstory: NRG was founded in 2018 by Neil Miller, Richard Rutter, and Grant Hawthorne. Despite the initial struggle to attract investors, the firm survived on grants from groups like Parkinson’s UK and the Michael J. Fox Foundation until it raised £16M in Series A in 2022. This £50M Series B was led by SV Health’s Dementia Discovery Fund, with backing from Merck KGaA and Novartis' venture arms. 🔎 Zoom in: NRG-5051 has a mechanism that blocks mPTP, a mitochondrial p … nt Hang on, I just got this, it's TOO good! N,R,G = Energy NRG = Neil, Richard, Grant NRG = Mitochondria generate energy NRG Therapeutics Like Reply 5 Reactions 6 Reactions SUNEEL KUMAR REDDY SIRIGIRI 9mo Report this comment Congratulations to the NRG Therapeutics team on securing £50M in funding! A significant milestone that brings real hope for patients with Parkinson’s and ALS. Looking forward to seeing NRG-5051 progress into clinical trials — a promising step to … neuroscience biotech company led Co-founder & CEO Neil Miller & CFO/Coo Grant Hawthorne . Developing mitochondria-targeted small molecule therapeutics for neurodegenerative diseases. The company’s proprietary technology focuses on inhibiting the mitochondrial permeability transition pore (mPTP) to protect neurons from cell death - a key factor in diseases like Parkinson’s disease, ALS (MND), and other chronic neurological conditions. 💰 Total Funding – NRG Therapeutic … nnounced September 2025). 📈 Investors: SV Health Investors' Dementia Discovery Fund (DDF) , The Michael J. Fox Foundation for Parkinson's Research , TARGET ALS FOUNDATION, INC . Omega Funds , Innovate UK , Parkinson's UK 🚀 The new capital will be used to: 1️⃣ Advance NRG-001 into first-in-human clinical trials for Parkinson’s disease 2️⃣ Delive
Resources | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a se … n membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Joi … s Bank has made a £50 million cornerstone commitment to Epidarex Capital’s next fund. Member news 13 January 2026 OutSee completes oversubscribed seed funding round OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round. Member news BIA Members' only 11 December 2025 Finance skills: Raising capital for biotech growth The first in a new serie … together to connect and network. Combined with the news of two new significant fund raises from Sofinnova and Medicxi and progress towards completion of the British Growth Partnership Fund, it did feel that the sector found a lot to be hopeful about. Blog 27 October 2025 UK biotech financing July - September 2025 New Q3 financing data reveals how these pressures are reshaping UK venture capital and exposing a fragile moment for the sector. The findings underscore the urgent
%PDF-1.7 %���� 362 0 obj > endobj xref 362 18 0000000016 00000 n 0000001770 00000 n 0000001927 00000 n 0000001971 00000 n 0000002947 00000 n 0000003061 00000 n 0000005442 00000 n 0000005990 00000 n 0000006547 00000 n 0000006634 00000 n 0000007143 00000 n 0000007749 00000 n 0000008012 00000 n 0000008616 00000 n 0000012481 00000 n 0000024807 00000 n 0000027814 00000 n 0000000656 00000 n trailer ]/Prev 17283108>> startxref 0 %%EOF 379 0 obj >stream hެT�Ou�z�k� ��ek�=~ Kɺn�uw-g��Aa������v�/��%�\凇�K�t3Q�0�8 B2�,&�C�F�b�f)��{��\��w���I�����y>����p]'� ?3l��( �������N��� p�aH�c��Ȇ�B7 … {��Z����ͭ��� ���P� ���f����q�¶0�%n�_i-))t�Ԙ�ZJW���l��3}]� Z�dw�~Z� �a�rFp���2������i/;�`,5U ����T[��c9���yQ��-Q�v��T���\l%�P� �Ό �� s�%�%��e�[� Ӡ��Mq�UH�-�4ڝS-�1�u�n��\��Z���� �+����lÝ� %YU��yrH����G[[�k�k!r�u�Zh�!j��ݶ�{�Ze[�?�EE��T)��[�!e炛Nsʄ�9$ӅDa���e�F,t��w��]N�S���=�@A_A����sn�b=�t-�բ�K��:�v˽�ػF�b:G�rJ�:� s!�֝�q�aM���;i��Q���������@�E ��f&�kF����4ۑיN�RO�-���QZ�Ԑ��C�y��#� �GS��UU+�9��ڢ 4�RJR7'��]i4��B :�U��(-��pn�.�D8n ���0 �R# A … ) 2023-06-01T09:59:16-07:00 2026-01-16T10:25:06-05:00 2026-01-16T10:25:06-05:00 application/pdf uuid:179172cb-df57-514c-bb7b-b597b921b949 adobe:docid:photoshop:48294714-270a-0c40-899c-87623942bbd3 xmp.did:5ef08acd-6dca-4528-8c94-45299bf36579 created xmp.iid:5ef08acd-6dca-4528-8c94-45299bf36579 2023-06-01T09:59:16-07:00 Adobe Photoshop 23.5 (Macintosh) saved xmp.iid:6a781d8e-da49-46a2-be04-77f01762e626 2023-06-01T10:01:58-07:00 Adobe Photoshop 23.5 (Macintosh) / converted from … T10:01:58-07:00 Adobe Photoshop 23.5 (Macintosh) / converted from image/tiff to application/pdf derived converted from image/tiff to application/pdf saved xmp.iid:33e7d684-9560-4a58-a6e3-bdd915c61cd5 2023-06-01T10:01:58-07:00 Adobe Photoshop 23.5 (Macintosh) / saved xmp.iid:7630515d-17ef-470e-a907-098d096b4e79 2026-01-16T10:24:47-05:00 Adobe Photoshop 26.11 (Macintosh) / xmp.iid:6a781d8e-da49-46a2-be04-77f01762e626 xmp.did:5ef08acd-6dca-4528-8c94-45299bf36579 xmp.did:5ef08acd … 000/10000 2 65535 1445 2173 endstream endobj 37 0 obj > endobj 38 0 obj >stream application/postscript PD GENE (Ora Presby) 2025-07-17T14:06:37-04:00 2025-07-17T14:06:37-04:00 2025-07-17T14:06:37-04:00 Adobe Illustrator 29.5 (Macintosh) xmp.iid:b055e233-96c7-40c8-9be1-37439509cc81 xmp.did:b055e233-96c7-40c8-9be1-37439509cc81 uuid:5D20892493BFDB11
NRG raises £50m to start trials of Parkinson's, ALS drug | pharmaphorum Skip to main content Tuesday 23 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research &a … ast October, and the clinical programme is also being supported by a $5 million grant from the Michael J Fox Foundation that is going towards initial manufacturing and toxicology work, the development of a PET tracer to track where it is working in the central nervous system, and identifying and validating biomarkers that can be used as surrogate endpoints in clinical trials. "Developing new drugs to treat neurological diseases is very challenging, but is receiving increased … g Parkinson's." The Series B was led by SV Health Investors' Dementia Discovery Fund, and included new investors British Business Bank, M Ventures, Novartis Venture Fund, and Criteria Bio Ventures, along with existing investors Omega Funds and Brandon Capital. In the first half of this year, the UK life sciences sector raised £1.23 billion in new venture capital backing, putting it on course to at least match the 2024 total for the full year, although, there have been signs o
Finance Report 2022 – Biotech Finance Skip to content UK biotech financing 2022 The latest UK Biotech Financing Report, published by the BioIndustry Association (BIA) and Clarivate Overview Executive summary Forewords Equity Venture capital Public markets Mergers and acquisitions Business deals Licensing Other finance Debt R&D grant funding Clinical pipeline Patents R&D Overview Forewords Executive summary Equity Venture capital Public markets Business deals Mergers and acquisitions Licensing Other finance Debt R&D grant funding R&D Patents Clinical pipeline Other repor … s the UK Government’s Life Sciences Investment Envoy by the Business Secretary, Grant Shapps MP. My mission is to increase the availability of capital for our growing sector. The UK’s strength in life sciences is undisputed with UK companies attracting significant levels of foreign capital, especially from expert US investors who see the quality of our science. But to have a sustainable life sciences industry in the UK we must rebuild the domestic investment ecosystem. The go … active investors in UK biotechs in 2022 by deal count. BIA Lifetime Achievement Award winner and founder of Abcam, Jonathan Milner, was the most active angel investor, with at least four disclosed investments. UK biotech’s attractiveness as a global investment location is clearly demonstrated by the fact that the top 24 financings all involved international investors. Within the top ten, eight deals were led by non-UK investors, largely from the US. Of all the VC deals in 202 … funds raised with mandate that allows investment in UK companies Investor name Fund name Fund size (£m) Date closed LSP LSP 7 832 11/02/2022 Frazier Life Sciences Frazier Life Sciences XI 750 17/03/2022 Sofinnova Partners Sofinnova Capital X 411 19/10/2022 Forbion Forbion Growth Opportunities Fund II 371 09/06/2022 Catalio Capital Management Catalio Nexus Fund III 305 03/05/2022 Oxford Science Enterprises Oxford Science Enterprises 250 18/07/2022 Cambridge Innova … prises 250 18/07/2022 Cambridge Innovation Capital Cambridge Innovation Capital Fund II 225 26/04/2022 Northern Gritstone Northern Gritstone 215 20/05/2022 Time BioVentures Time BioVentures 1 LP 86 27/10/2022 Rapha Capital Management Rapha Capital BioVentures Fund I 80 03/05/2022 Dr Uzma Choudry Investor, Octopus Ventures Despite being home
Life Sciences Law Firm | Healthcare Solicitors & Lawyers | Withers Skip to main content Contact Newsroom Insight English Français Italiano Español 日本語 繁體中文 简体中文 Menu Home Experience Back Experience Find out about our practices, the types of clients we help and the sectors in which we operate Experience overview Our practices Back Our practices Our practices overview Banking and finance Back Banking and finance Banking and finance Acquisition and leveraged finance Asset-backed and luxury asset finance Com … Immigration Back Immigration Immigration Expatriation Global mobility Passports Residency and green cards Visas Toggle Immigration menu International arbitration Back International arbitration International arbitration Business and human rights Investment treaty arbitration Public international law Sanctions Toggle International arbitration menu Investment funds Back Investment funds Investment funds Financial services regulatory Investment structuring Private equity Toggle I … ningside Venture Investments Limited and BridgeEdge, the impact venture capital fund of the American Cancer Society UK, Hong Kong, US In3Bio Research Our UK and Boston Life Sciences team acts as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials. UK, Malaysia Parkinson's UK NRG Therapeutics - We advised Park … nd IP protection UK Alnylam Pharmaceuticals Drafted numerous provisional patent application. Developed a worldwide patent portfolio We developed a worldwide patent portfolio for IN3Bio (Cancer Vaccine Company) that includes 10 patent families in about 13 jurisdictions US, Malaysia, Cuba, Europe Omega Therapeutics Provided extensive counseling regarding nucleic acid therapeutic delivery vehicles. US, Europe Fulcrum Therapeutics Drafted numerous patent ap … ningside Venture Investments Limited and BridgeEdge, the impact venture capital fund of the American Cancer Society UK, Hong Kong, US In3Bio Research Our UK and Boston Life Sciences team acts as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third
Parkinson's UK Programme Stream at the International Festival of Neuroscience | The British Neuroscience Association BNA2023 online Book of abstracts Event app Full programme Partnering organisations Parkinson's UK stream Guarantors of Brain stream Plenaries Programme topics Workshops & special sessions Rest & Restore Room Supporters Student & ECR social Festival journal Sustainability Children & carers Mental wellbeing Public events Sponsorship & exhibition Why come to BNA2023? About BNA2023 BNA2023 Programme Parkinson's UK: Festival Partner Programme Stream Pa
Charlotte Kremers - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln Charlotte Kremers Principal Charlotte Kremers, PhD, is an Associate in the Biotechnology team, having joined M Ventures as a Fellow in September 2022. Charlotte received her BSc in Cell Biology, Physiology and Neuroscience from University College Utrecht and MSc in Neuroscience from University College London. She completed her PhD in Neuroscience at UCL in 2022, during which she investigated the pathomechanisms underlying a juvenile form of Amyotrophic Lateral Sclero
New Approaches to the Treatment of Parkinson’s Disease - RSC BMCS --> Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th RSC-BMCS/RSC-SCI GPCRs in Medicinal Chemistry RSC-BMCS/SCI Targeted Protein Degradation 2026 BMCS Hot Topics: AI in Drug Discovery 2026 BMCS Antibody-Drug Conjugates 2026 20th Postgraduate Symposium 11th RSC-BMCS Symposium on Mastering Medicinal Chemistry 9th RSC/SCI Ion Channels as Therapeutic Targets BMCS Event archive Event archive from Maggi Churchouse Awards BMCS Hall of Fame … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th R … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Events New Approaches to the Treatment of Parkinson’s Disease Charlotte Turpin 2025-11-14T15:58:23+00:00 BMCS New approaches to the treatment of Par … ss the abstract template. All submissions should be emailed to [email protected] Deadline for submissions – Midnight (BST) 5th September, 2025. Student Bursaries The RSC-BMCS are offering a small number of bursaries to attend the meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions or non-profit institutions. Preference will be given to members of the RSC-BMCS. Bursary applications are also invited from RSC or EFMC memb … have difficulty in funding their attendance. Please click here to complete the application form. Please send all completed application forms to [email protected] Registration Registration is now open, please click here to register! In person registration fees RSC Member £180 Non Member £210 RSC Student Member £100 Student Non-Member £130 Online a
Osler Diagnostics has raised $85 million Series C. NRG Therapeutics has raised £16 million Series A. Kalium Health has raised over-subscribed investment round. about sponsor subscribe subscribe Thank you! Welcome to Cambridge Biocapital. Oops! Something went wrong while submitting the form. Make sure you submit a valid email. 031 Osler Diagnostics has raised $85 million Series C. NRG Therapeutics has raised £16 million Series A. Kalium Health has raised over-subscribed investment round. Nov 14, 2022 Osler Diagnostics has raised $85 million Series C. NOV, 14 | #031 Summary Startup Funding New … make sure you leave space to go visit the Taylor Wessing Photographic Portrait Prize 2022 exhibition. Music? Peter Yorn and Scarlett Johansson . Now, ask for a large cappuccino, there is a lot to get through. Let’s dive in! Startup Funding News Oxford-based Osler Diagnostics has raised $85 million Series C. The funding was led by M&G Investments and participated by existing investors including Oxford Science Enterprises , Braavos Investment Advisers , and Lansdowne Partn … iness, Energy, and Industrial Strategy , and Ian Shott CBE FREng . Applications deadline is November, 28 and the 6-months program starts in March 2023. The accelerator program does not take equity or charge fees. It provides a £10,000 grant for leaddership training, monthy one-to-one mentorship, training workshops, free access to the Taylor Centre (central London office) and to its regional hub in Ormeau Baths , Belfast; travel and accommodation expenses covered, and Lifetime … uth West England. The majority of the commitment will be invested alongside SCV Fund 2, while a small proportion will be used for co-investments through the existing SCV EIS Fund (SCV Fund 1). Science Create Ventures portfolio includes Carbometrics , Cytoseek , OxDx , imophoron , and Portal Biotech , among others. LifeArc has launched a new fund for gene therapy technologies. The fund has a £5 million annual capacity and includes support from the world-class network of Innova … upport from the world-class network of Innovation Hubs for Gene Therapies . The fund will provide grants to academic researchers working to advance gene therapies from preclinical research to early clinical studies, including the manufacturing and clinical costs. Successful projects will be awarded additional funding. Swedish EQT 's (EQTAB.S
ALS Research Insights from TRICALS Masterclass 2026 | NRG Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview … s recent £50m series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) in a syndicate of leading international life science venture investors that also included British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. The new funds provide runway for completion of a Phase 2 clinical proof of concept study of NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neuron di … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes. Follow us on LinkedIn. Media Contact Information : Media enquiries (for NRG Therapeutics) Sue Charles, Charles Consultants - +44 796
NRG Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies NRG Therapeutics NRG Therapeutics is a neuroscience-focused drug discovery company dedicated to developing disease-modifying treatments for neurodegenerative disorders such as Parkinson’s and ALS. The company leverages breakthrough science in mitochondrial biology to identify new therapeutic targets, focusing on inhibitors of the mitochondrial permeability transition pore (mPTP) that are orally bioavailable and brain-penetrant. Their mission is to slow or halt … ates NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases NRG5051 is a first-in-class inhibitor of the mitochondrial permeability transition pore (mPTP) designed to penetrate the brain when taken orally. It has shown neuroprotective effects in preclinical models of Parkinson’s and ALS, and the company has secured a $5 million grant from The Mic … ation to support its development into clinical trials. NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND NRG received a grant from Target ALS to support its discovery program for small molecule inhibitors of the mPTP as treatments for ALS. The project aims to validate a new mitochondrial drug target and develop therapies that can prevent mitochondrial dysfunction and neurodegeneration in ALS mo … ams targeting neurodegenerative diseases. NRG Therapeutics Awarded Second $500K Grant from The Michael J.. Fox Foundation to Further Progress Parkinson’s Programme NRG received a second grant from MJFF to validate a novel mitochondrial drug target for Parkinson’s and to develop NRG5051 into clinical trials, with anticipated first-in-human studies by 2025. Case Study: Life Sciences - Future50 PwC highlights NRG Therapeutics as a leading biotech in the life sciences sector. 9 n … ch features NRG Therapeutics among notable neuroscience biotech companies. MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's Bioworld reports on NRG’s grant from MJFF to develop mitochondrial drug targets for Parkinson’s. NRG raises Series A funds for Parkinson’s and ALS therapy development
Paul Thompson Joins NRG as Chief Development Officer | NRG Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr … a regulatory meeting in September, the agency indicated it would reconsider the application with additional information from HOPE-3. 🔵 The Phase 3 study met both primary endpoints, preserving upper limb function and supporting cardiac output. 🔵 Analysts noted the results exceeded expectations, given prior sentiment was mixed. 🔵 Capricor’s stock rose more than 300%, jumping from $6.36 and up to $40 before stabilizing around $25. 🔵 If approved, deramiocel would become the f … s potential to meaningfully alter the disease trajectory. Capricor now plans to submit a formal response to the FDA’s earlier rejection letter, incorporating the new HOPE-3 data. The company emphasized its prior alignment with regulators on the path forward. This update underscores how pivotal late-stage data can reshape regulatory expectations, clinical pathways, and market outlooks for high-need rare disease therapies. 👉 Follow Sadhna Bokhiria & KIRIA Research for evid
Brandon Capital Invests in Neuroscience Company NRG Therapeutics – Brandon BioCatalyst Toggle navigation About us Our story Members Board Investors Government Partners Membership Benefits Investment Process Investments Training Biotech Innovators Program Cicada x Brandon BioCatalyst at Westmead Brandon BioCatalyst Internship Queensland TACSGP Women in Leadership Development (WILD) CUREator About Programs Process and Investment Review Committee Portfolio Outcomes OPEN ROUND: BioMedTech Incubator News Our Stories Brandon Capital Invests in Neuroscience Company NRG Therapeutics --> Brandon … r drug discovery based on these pioneering studies funded by a Drug Development grant awarded to WEHI from FightMND, under which NRG is the Industrial Partner. Following the financing, Professor Masters has joined the NRG management team as VP of Discovery Biology. His laboratory at WEHI in Melbourne, Australia, will also include a sponsored team as part of an expanded research agreement between NRG and WEHI. Jonathan Tobin, Partner at Brandon Capital said , “We are delighted … Parkinson’s UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to the Walter and Eliza Hall Institute (WEHI). Follow us on Twitter and LinkedIn . About WEHI (Walter and Eliza Hall Institute of Medical Research) – www.wehi.edu.au WEHI is where the world’s brightest minds collaborate and innov
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson's and ALS Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Mult … Parkinson's UK, Omega Funds and Brandon Capital. The company has also received grant funding from The Michael J. Fox Foundation, Innovate UK (Biomedical Catalyst Award), and is the industrial partner for a FightMND Drug Discovery grant awarded to WEHI (Walter and Eliza Hall Institute of Medical Research). Follow us on Twitter and LinkedIn . About Omega Funds – https://omegafunds.com/ Founded in 2004, Omega Funds is a leading international venture capi … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Feb 9, 2023 NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK Joins from Evotec
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Apr 19, 2023 NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders Vad Lazari Ph.D., appointed to newly created position of VP of Biology, based in Stevenage, UK Joins from Charles River an
Dr Richard Seabrook joins Board of NRG Therapeutics - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Nov 5, 2019 Dr Richard Seabrook joins Board of NRG Therapeutics Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development. During his time at The Wellcome Trust Richard established a £200 million Seeding Drug Discovery fund which facilitated small molecule development and ear
NRG Therapeutics Announces Further Expansion with the --> Accessibility: Skip TopNav NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer December 01, 2025 04:00 ET | Source: NRG Therapeutics Limited NRG Therapeutics Limited STEVENAGE, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson, PhD, as Chief Development Office … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes. Follow us on LinkedIn . GlobeNewswire
NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Dec 1, 2025 NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND - SV Health Investors Strategy Therapeutics Healthcare Growth Medtech People Portfolio News Contact Investors SV8 Biotech Fund SV7+ Growth Fund Dementia Discovery Fund-2 SV Biotech Crossover Opportunities Fund SV7 Impact Medicine Fund SV7 Growth Fund Dementia Discovery Fund-1 SV Life Sciences Funds 5-6 SV Fund IV Continuation Fund SV Life Sciences Funds 3-4 NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Da … 025 Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP) The mPTP is a well-e … s B financing. The financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia. DDF was joined by a syndicate of leading international life science venture investors: British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. Founding investor Parkinson’s UK via i … k), Charlotte Kremers (M Ventures) and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board of directors. In addition, the company is delighted that Professor David Dexter, Director of Research at Parkinson’s UK, has been appointed as a special advisor on Parkinson’s. About NRG Therapeutics NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegene … andon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes.
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Nov 9, 2022 NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS £16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studie
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press release Apr 26, 2023 NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair. Jonathan’s appoint
Press Releases - NRG Therapeutics Home About Us Team Investors & Partners Science Pipeline News Press Releases In the News Meet us at Contact --> © 2026 NRG Therapeutics Press releases Jan 8, 2026 NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s READ MORE > Dec 1, 2025 NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer READ MORE > Oct 23, 2025 NRG Therapeutics Announces Senior Appointmen … 2024 NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases READ MORE > Sep 5, 2024 NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND READ MORE > Apr 26, 2023 NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair READ MORE > Apr 19, 2023 NRG Therapeuti … c Advisory Board READ MORE > Feb 22, 2023 NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme READ MORE > Feb 9, 2023 NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders READ MORE > Nov 9, 2022 NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS READ MORE … oject... READ MORE > May 30, 2022 NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease... READ MORE > Mar 1, 2022 NRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant READ MORE > Dec 16, 2021 NRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia READ MORE > Aug 23, 2021 Parkinson’s … rug Discovery Programme READ MORE > Jul 29, 2021 NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme READ MORE > Aug 7, 2020 Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd READ MORE > Nov 5, 2019 Dr Richard Seabrook joins Board of NRG Therapeutics READ MORE > Jul 1, 2019 Cha
"NRG Therapeutics raises £50m for Parkinson's drug NRG5051" | Parkinson's UK posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … ook X To view or add a comment, sign in SV Health Investors' Dementia Discovery Fund (DDF) 4,873 followers 9mo Report this post We are excited to lead NRG Therapeutics ’ oversubscribed £50m Series B financing alongside new co-investors British Business Bank , Novartis Venture Fund, M Ventures and Criteria Bio Ventures , with continued support from Omega Funds and Brandon Capital . The financing will advance NRG’s lead asset, NRG5051, a first-in-class oral mitochondrial permea … is post Alterity Therapeutics has secured $20m through a strategic placement to fund ATH-434's development, unpacked by Tylah Tully in Stockhead's latest Break it Down. https://buff.ly/213NHzR #ASX Break it Down: Funding boost for Alterity’s MSA drug candidate - Stockhead stockhead.com.au 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in CARB-X 13,885 followers 8mo Report this post CARB-X is live in London for the first day of the inaugural Globa … Europe Equity Opportunities ETF (FPXE), the takeover adds +70 bps. alpha to the fund and underscores the ongoing wave of post-IPO M&A in biotech and beyond. Source: https://lnkd.in/eenzsWj2 #IPO #MnA #Healthcare #Biotech #Takeover #ETF #FPXE #IPOMnA #GrowthInfusion #GNDX Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion bloomberg.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Josef Schuster 8mo Edited Report this post BREAKING N … Europe Equity Opportunities ETF (FPXE), the takeover adds+70 bps. alpha to the fund and underscores the ongoing wave of post-IPO M&A in biotech and beyond. Source: https://lnkd.in/gBWrnTVF #IPO #MnA #Healthcare #Biotech #Takeover #ETF #FPXE #IPOMnA #GrowthInfusion #GNDX Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion bloomberg.com
NRG Therapeutics closes oversubscribed series B, takes NRG5051 into clinic | Lynsey Bilsland posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … RG Therapeutics team, the new investors SV Health Investors' Dementia Discovery Fund (DDF) , British Business Bank , Novartis Venture Fund, M Ventures and Criteria Bio Ventures, and existing investors Brandon Capital, Omega Funds and look forward to working with you! Parkinson's UK Parkinson's Foundation #causetocure NRG Therapeutics 4,248 followers 9mo FINANCING NEWS - We are thrilled to have announced our oversubscribed £50m ($67m) series B financing, which will enable NRG … hase 1b study. The financing was led by SV Health Investors' Dementia Discovery Fund (DDF) , a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia, alongside other new investors British Business Bank , M Ventures , Novartis Venture Fund and Criteria Bio Ventures , together with existing investors Omega Funds and Brandon Capital . Founding investor Parkinson's UK via its drug development arm the #Parkinson ’sVirtua … kd.in/eivHvBgY Congratulations to our founders Neil Miller , Richard Rutter and Grant Hawthorne , and the whole of the NRG team. Thanks to our many collaborators including seth masters , and CRDMO partners that have supported us on our journey. Thank you also to the organisations that have provided invaluable grant funding: The Michael J. Fox Foundation for Parkinson's Research , Target ALS , The ALS Association , and Innovate UK . Huge appreciation to our legal team from Mil … hase 1b study. The financing was led by SV Health Investors' Dementia Discovery Fund (DDF) , a specialist venture fund dedicated to investing in companies developing or enabling novel therapeutics for dementia, alongside other new investors British Business Bank , M Ventures , Novartis Venture Fund and Criteria Bio Ventures , together with existi
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia